在本研究中，我们制备了仿生硒黄芩素纳米颗粒（ACM-SSe-BE）用于非小细胞肺癌的靶向治疗。由于A549膜的涂层，该系统具有同源靶向能力，可以制备靶肿瘤细胞。硒纳米粒子（SSe）和黄芩素（BE）之间的硼酸酯键对pH敏感，在肿瘤微环境的酸性条件下可以断裂，实现BE在肿瘤部位的靶向释放。此外，SSe通过增加肿瘤细胞中ROS的产生进一步增强BE的抗肿瘤作用。透射电子显微镜 (TEM) 图像和动态光散射 (DLS) 显示 ACM-SSe-BE 的粒径约为 155 ± 2 nm。 FTIR 验证了 SSe 和 BE 的成功偶联。体外释放实验表明，ACM-SSe-BE 在 pH 5.5 下 24 h 后的累积释放量为 69.39 ± 1.07%，低于 pH 7.4 下的 20% 释放量，证实了 ACM-SSe-BE 中 BE 的 pH 敏感释放。 SSe-BE。细胞摄取实验和体内成像表明ACM-SSe-BE具有良好的靶向能力。 MTT、流式细胞术、Western blot和细胞免疫荧光染色结果表明ACM-SSe-BE促进A549细胞凋亡并抑制细胞增殖。体内抗肿瘤结果与细胞实验结果一致。这些结果清楚地表明ACM-SSe-BE将成为一种有前途的用于治疗非小细胞肺癌的仿生纳米系统。

In this study, we prepared bionic selenium-baicalein nanoparticles (ACM-SSe-BE) for the targeted treatment of nonsmall cell lung cancer. Due to the coating of the A549 membrane, the system has homologous targeting capabilities, allowing for the preparation of target tumor cells. The borate ester bond between selenium nanoparticles (SSe) and baicalein (BE) is pH-sensitive and can break under acidic conditions in the tumor microenvironment to achieve the targeted release of BE at the tumor site. Moreover, SSe further enhances the antitumor effect of BE by increasing the production of ROS in tumor cells. Transmission electron microscopy (TEM) images and dynamic light scattering (DLS) showed that the ACM-SSe-BE had a particle size of approximately 155 ± 2 nm. FTIR verified the successful coupling of SSe and BE. In vitro release experiments indicated that the cumulative release of ACM-SSe-BE at pH 5.5 after 24 h was 69.39 ± 1.07%, which was less than the 20% release at pH 7.4, confirming the pH-sensitive release of BE in ACM-SSe-BE. Cell uptake experiments and in vivo imaging showed that ACM-SSe-BE had good targeting ability. The results of MTT, flow cytometry, Western blot, and cell immunofluorescence staining demonstrated that ACM-SSe-BE promoted A549 cell apoptosis and inhibited cell proliferation. The in vivo antitumor results were consistent with those of the cell experiments. These results clearly suggested that ACM-SSe-BE will be a promising bionic nanosystem for the treatment of nonsmall cell lung cancer.